Eli Lilly (LLY) to Acquire Centessa Pharmaceuticals in $7.8B Deal

Eli Lilly and Company (NYSE:LLY) is one of the best US stocks to buy and hold for the next 3 years. On March 31, Eli Lilly announced an agreement to acquire Centessa Pharmaceuticals in a deal valued at $7.8 billion. The acquisition diversifies the company’s portfolio beyond metabolic treatments and establishes a presence in the sleep disorder market. Eli Lilly has offered $38 per share in cash, representing a 37.8% premium over Centessa’s recent closing price, along with a contingent value right worth ~$9 per share.

The acquisition focuses on Centessa’s development of orexin agonists, a new class of treatments designed to regulate the brain’s sleep-wake cycle. The company’s lead drug candidate, cleminorexton, is currently in mid-stage clinical studies for the treatment of narcolepsy and idiopathic hypersomnia.

Analysts suggest that the market for narcolepsy drugs, currently valued at $2.5 billion, could expand with the introduction of these types of high-performance medical solutions. This deal follows several recent acquisitions by Eli Lilly and Company (NYSE:LLY) and aligns with the company’s efforts to address the widespread impact of sleep disorders, which affect an estimated 50 million to 70 million Americans.

Eli Lilly and Company (NYSE:LLY) is a healthcare company that specializes in human pharmaceutical products and offers cardiometabolic health & oncology products.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None.  Follow Insider Monkey on Google News.